Invention Grant
US08173674B2 Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals
有权
磺酰基 - 苯基-2H- [1,2,4]恶二唑-5-酮衍生物,其制备方法及其作为药物的用途
- Patent Title: Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals
- Patent Title (中): 磺酰基 - 苯基-2H- [1,2,4]恶二唑-5-酮衍生物,其制备方法及其作为药物的用途
-
Application No.: US12480974Application Date: 2009-06-09
-
Publication No.: US08173674B2Publication Date: 2012-05-08
- Inventor: Stefanie Keil , Matthias Urmann , Karl Schoenafinger , Wolfgang Wendler , Maike Glien , Hans-Ludwig Schaefer , Eugen Falk
- Applicant: Stefanie Keil , Matthias Urmann , Karl Schoenafinger , Wolfgang Wendler , Maike Glien , Hans-Ludwig Schaefer , Eugen Falk
- Applicant Address: FR Paris
- Assignee: Sanofi-Aventis
- Current Assignee: Sanofi-Aventis
- Current Assignee Address: FR Paris
- Agency: Scully, Scott, Murphy & Presser, P.C.
- Agent Jiang Lin
- Priority: EP06025880 20061214
- Main IPC: C07D401/02
- IPC: C07D401/02 ; A61K31/47
![Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals](/abs-image/US/2012/05/08/US08173674B2/abs.jpg.150x150.jpg)
Abstract:
The invention relates to sulfonyl-phenyl-oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity.What are described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
Public/Granted literature
Information query